A systematic review and meta-analysis [77] involving 4527 advanced NSCLC patients indicated that compared to tumor tissue, the combined sensitivity and specificity of ctDNA EGFR mutation in plasma samples was 0.70 and 0.98, respectively. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.